Net profit for the period was up marginally by about 2% year-on-year to Rs 1,042 crore. It was impacted by one-time adjustment of gratuity and leave encashment liability due to the government’s new labour code. Excluding the one-time adjustment, net profit rose 9% to Rs 1,110 crore.
EBITDA for the quarter increased 31% to Rs 1,816.40 crore, while EBITDA margin for the quarter stood at 26.5%.
Sharvil Patel, Managing Director – Zydus Lifesciences, said: “Our robust performance in 3QFY26 across key businesses reinforces the strength and scalability of our base business.”
“Our disciplined M&A and business development strategy is translating into tangible results, laying a strong foundation for sustained value creation,” he added.
Within pharmaceutical business, India branded formulations sustained the growth momentum and outpaced the market growth. US base business continued to grow driven by persistent volume expansion and new launches, while international markets business further accelerated its growth trajectory across regions .
India formulations revenue stood at Rs 17,09.40 crore, up 13% y-o-y, and accounted for 25% of consolidated revenues.Its North America revenue stood at Rs 28,04.30 crore, up 16% y-o-y. The business accounted for 41% of consolidated revenues. In constant currency terms, the business registered revenues of $314 million.